Our landmark EXALT-1 clinical study (clinical trial NCT03096821) was just published in Cancer Discovery. Here, we could demonstrate for the first time that functional precision-oncology can improve patient outcome in a prospective interventional trial. For 56 patients suffering aggressive blood cancers, their next treatment was adapted to their personal drug screening (pharmacoscopy) results, and we followed them on average for another 2 years. The results:
“30 Patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease.”
Kornauth et al., Cancer Discovery, 2022
Prof. Dr. Tony Letai, professor in Medicine at Harvard Medical School and Dana Farner Cancer Institute, has written a great accompanying commentary as well as review on the topic.
Also check out the News article at the ETH Zurich!